Adenosine deaminase deficiency: Difference between revisions
m Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +) |
Gerald Chi- (talk | contribs) mNo edit summary |
||
Line 13: | Line 13: | ||
MeshID = | | MeshID = | | ||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | {{SI}} | ||
{{CMG}} | |||
==Overview== | |||
'''Adenosine deaminase deficiency''', or '''ADA deficiency''', is an inherited [[immunodeficiency]] [[syndrome]] accounting for about 25% of all cases of [[severe combined immunodeficiency]] (SCID). | '''Adenosine deaminase deficiency''', or '''ADA deficiency''', is an inherited [[immunodeficiency]] [[syndrome]] accounting for about 25% of all cases of [[severe combined immunodeficiency]] (SCID). | ||
Line 36: | Line 39: | ||
{{Immune disorders}} | {{Immune disorders}} | ||
[[Category:Genetic disorders]] | [[Category:Genetic disorders]] | ||
[[Category:Inborn errors of metabolism]] | [[Category:Inborn errors of metabolism]] | ||
Revision as of 20:36, 3 June 2016
Adenosine deaminase deficiency | |
ICD-10 | D81.3 |
---|---|
ICD-9 | 279.2 |
OMIM | 102700 |
DiseasesDB | 260 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Adenosine deaminase deficiency, or ADA deficiency, is an inherited immunodeficiency syndrome accounting for about 25% of all cases of severe combined immunodeficiency (SCID).
This disease is due to a lack of the enzyme adenosine deaminase coded for by a gene on chromosome 20. There is an accumulation of dATP, which causes an increase in S-adenosylhomocysteine; both substances are toxic to immature lymphoid cells, so fail to reach maturity. As a result, the immune system of the afflicted person is severely compromised or completely lacking.
The enzyme adenosine deaminase is important for purine metabolism.
Treatment
- bone marrow transplant
- gene therapy (efforts halted due to increased incidence of leukemia)
- ADA enzyme in PEG vehicle
- Stem Cell Therapy(still in the experimental stage)
The first gene therapy to combat this disease was performed by Dr. W. French Anderson on a 4yr old girl, Ashanti DeSilva, in 14 September 1990 at the National Institute of Health, Bethesda, Maryland, U.S.A.
The therapy performed was the first successful case of gene therapy.
External links
- Gene Therapy: A Brief History: [2]